Neumora Therapeutics develops novel therapies for brain diseases, focusing on neuropsychiatric disorders and neurodegenerative conditions through programs with new mechanisms of action. The clinical-stage biopharmaceutical company uses precision approaches to address unmet needs in central nervous system disorders that have long relied on limited treatment classes. It advances candidates via internal discovery and business development partnerships aimed at better patient outcomes.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -68 | — |
| Q2 2025 | 0 | — | -52.7 | — |
| Q3 2025 | 0 | — | -56.8 | — |
| Q4 2025 | 0 | — | -59.5 | — |
| Q1 2026 | 0 | — | -53.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Alliance Entertainment Holding Corporation (AENT), Oceanhawk Acquisition Corp (OHAC), NeoVolta Inc. (NEOV), McKinley Acquisition Corporation (MKLY), QDRO Acquisition Corp. (QADR), Limoneira Company (LMNR)